Vivani Medical, Inc. (VANI) announced promising preclinical results for its exenatide implant, demonstrating a significant reduction in liver fat in obese mice. This implant, which delivers the drug exenatide (sold as Byetta and Bydureon for diabetes), could potentially offer a highly differentiated treatment option for obesity and related metabolic disorders. Vivani is preparing to launch its first human clinical trial, LIBERATE-1, later this year.